Back to top

Supernus Pharmaceuticals: Strong Product Performance and Strategic Management Drive Buy Rating

Supernus Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Stacy Ku from TD Cowen maintaine...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Supernus Pharmaceuticals, Inc. (SUPN)